Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanfanercept in Dry Eye Disease
NCT06400589Phase 3Suspended
- Sponsor
- HanAll Biopharma
- Start
- May 2024
- Primary completion
- Aug 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanfanercept in dry eye disease (DED) (3 arms), sponsored by HanAll Biopharma. Primary endpoint: Schirmer Test at 12 weeks. Started May 2024; status: suspended.
02
Drugs
tanfanercept
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06400589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400589.